Acorda Therapeutics Stock Forecast, Price & News

+0.26 (+6.62 %)
(As of 04/16/2021 04:00 PM ET)
Today's Range
Now: $4.19
50-Day Range
MA: $5.23
52-Week Range
Now: $4.19
Volume173,511 shs
Average Volume920,286 shs
Market Capitalization$39.76 million
P/E Ratio0.76
Dividend YieldN/A
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Selincro for the treatment of alcohol dependence; and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
Acorda Therapeutics logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:ACOR
Year FoundedN/A



Sales & Book Value

Annual Sales$192.41 million
Cash Flow$18.22 per share
Book Value$38.82 per share


Net Income$-272,970,000.00


Market Cap$39.76 million
Next Earnings Date5/4/2021 (Estimated)


Acorda: Q4 Earnings Snapshot
March 4, 2021 |
Seagen (SGEN) Submits BLA to FDA for Cervical Cancer Drug
February 11, 2021 |
See More Headlines


Overall MarketRank

1.42 out of 5 stars

Medical Sector

633rd out of 2,024 stocks

Biological Products, Except Diagnostic Industry

91st out of 177 stocks

Analyst Opinion: 3.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -
+0.26 (+6.62 %)
(As of 04/16/2021 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ACOR News and Ratings via Email

Sign-up to receive the latest news and ratings for ACOR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Acorda Therapeutics (NASDAQ:ACOR) Frequently Asked Questions

Is Acorda Therapeutics a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acorda Therapeutics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Acorda Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACOR, but not buy additional shares or sell existing shares.
View analyst ratings for Acorda Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Acorda Therapeutics?

Wall Street analysts have given Acorda Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Acorda Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Acorda Therapeutics?

Acorda Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 1,070,000 shares, an increase of 40.6% from the February 28th total of 761,100 shares. Based on an average daily trading volume, of 1,050,000 shares, the days-to-cover ratio is presently 1.0 days. Currently, 11.5% of the company's stock are short sold.
View Acorda Therapeutics' Short Interest

When is Acorda Therapeutics' next earnings date?

Acorda Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Acorda Therapeutics

How were Acorda Therapeutics' earnings last quarter?

Acorda Therapeutics, Inc. (NASDAQ:ACOR) issued its earnings results on Wednesday, March, 3rd. The biopharmaceutical company reported ($2.50) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($2.57) by $0.07. The biopharmaceutical company earned $38.16 million during the quarter, compared to analysts' expectations of $34 million. Acorda Therapeutics had a negative trailing twelve-month return on equity of 8.60% and a net margin of 29.71%.
View Acorda Therapeutics' earnings history

How has Acorda Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Acorda Therapeutics' stock was trading at $6.06 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ACOR shares have decreased by 30.9% and is now trading at $4.19.
View which stocks have been most impacted by COVID-19

When did Acorda Therapeutics' stock split? How did Acorda Therapeutics' stock split work?

Shares of Acorda Therapeutics reverse split on Monday, January 4th 2021. The 1-6 reverse split was announced on Thursday, December 31st 2020. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 31st 2020. An investor that had 100 shares of Acorda Therapeutics stock prior to the reverse split would have 17 shares after the split.

What price target have analysts set for ACOR?

2 brokers have issued 1-year target prices for Acorda Therapeutics' shares. Their forecasts range from $6.00 to $35.00. On average, they anticipate Acorda Therapeutics' stock price to reach $23.67 in the next twelve months. This suggests a possible upside of 464.8% from the stock's current price.
View analysts' price targets for Acorda Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Acorda Therapeutics' key executives?

Acorda Therapeutics' management team includes the following people:
  • Dr. Ron Cohen, Founder, CEO, Pres & Director (Age 65, Pay $827.95k)
  • Mr. David Lawrence, CTO, Chief of Bus. Operations, Principal Accounting Officer & Principal Financial Officer (Age 63, Pay $480.9k)
  • Ms. Lauren M. Sabella, Chief Commercial Officer (Age 60, Pay $490.07k)
  • Dr. Burkhard Blank, Chief Medical Officer and Head of R&D (Age 66, Pay $662.5k)
  • Ms. Felicia Vonella, VP of Investor Relations
  • Mr. Andrew Mayer J.D., Sr. VP, Deputy Gen. Counsel & Corp. Sec.
  • Ms. Tierney Saccavino, Exec. VP of Corp. Communications
  • Ms. Denise J. Duca, Exec. VP of HR
  • Dr. Andrew R. Blight, Chief Scientific Officer Emeritus (Age 70)
  • Mr. Peter S. Carbone, Exec. VP of Quality

What is Ron Cohen's approval rating as Acorda Therapeutics' CEO?

39 employees have rated Acorda Therapeutics CEO Ron Cohen on Ron Cohen has an approval rating of 55% among Acorda Therapeutics' employees. This puts Ron Cohen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Acorda Therapeutics' key competitors?

What other stocks do shareholders of Acorda Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acorda Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), InterDigital (IDCC), Nektar Therapeutics (NKTR), Rigel Pharmaceuticals (RIGL), Novan (NOVN), SCYNEXIS (SCYX), Acasti Pharma (ACST) and Applied Materials (AMAT).

What is Acorda Therapeutics' stock symbol?

Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."

How do I buy shares of Acorda Therapeutics?

Shares of ACOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Acorda Therapeutics' stock price today?

One share of ACOR stock can currently be purchased for approximately $4.19.

How much money does Acorda Therapeutics make?

Acorda Therapeutics has a market capitalization of $39.76 million and generates $192.41 million in revenue each year. The biopharmaceutical company earns $-272,970,000.00 in net income (profit) each year or ($11.94) on an earnings per share basis.

How many employees does Acorda Therapeutics have?

Acorda Therapeutics employs 167 workers across the globe.

What is Acorda Therapeutics' official website?

The official website for Acorda Therapeutics is

Where are Acorda Therapeutics' headquarters?

Acorda Therapeutics is headquartered at 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502.

How can I contact Acorda Therapeutics?

Acorda Therapeutics' mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The biopharmaceutical company can be reached via phone at 914-347-4300.

This page was last updated on 4/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.